Twist Bioscience secures data pipeline role in Eli Lilly TuneLab's AI drug discovery ecosystem

Twist Bioscience Partners With Eli Lilly TuneLab for AI Drug Discovery

Twist Bioscience announced an agreement with Eli Lilly TuneLab, positioning itself as a preferred provider of antibody characterization data services for the collaborative AI/ML-driven drug discovery platform1

1

3

3

. Under the partnership, Twist will generate high-throughput wet lab antibody data using TuneLab-specified protocols, directly feeding into AbLab, Lilly's antibody developability prediction model2

2

. TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data valued at over $1 billion2

2

. More than 75 participating companies can now use TuneLab prediction models to accelerate molecule selection for drug candidates2

2

.

High-Quality Data Fuels AI Model Training

Emily Leproust, CEO and co-founder of Twist Bioscience, emphasized that AI model training depends entirely on data quality. "Twist has the scale and high-throughput capabilities to generate consistent and reliable antibody characterization data these models need to be trained on," Leproust stated3

3

. Through this arrangement, TuneLab users can order antibody services from Twist using preferred protocols to generate high-quality wet lab data with preferred pricing5

5

. This approach connects experimental data with AI-enabled discovery, allowing researchers to potentially accelerate antibody drug discovery while contributing data back to TuneLab for federated training5

5

.

Stock Surges on Strategic AI Pivot

Twist Bioscience shares rallied 5% to $144.90 following the announcement, with the stock trading near its 52-week high of $155.444

4

1

1

. The partnership reinforces Twist's strategic pivot toward AI-driven life science applications, a theme that has powered the stock's remarkable recovery from a 52-week low of $23.302

2

. Shares have more than quadrupled over the past year4

4

. The high-profile Eli Lilly endorsement, combined with Twist's established momentum in AI drug discovery, created a supportive market environment that pushed shares to an intraday high of $148.502

2

.

Broader Implications for Pharmaceutical Development

Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D, which together support biotech innovation by providing access to strategic capital, lab space, technology, and research and development capabilities5

5

. The TuneLab ecosystem lends the partnership significant credibility in pharmaceutical development circles2

2

. Other companies like Schrödinger have already integrated the platform into their drug discovery workflow, underscoring sector-wide momentum around AI-accelerated pharmaceutical development2

2

. In August, Anthropic selected Twist Bioscience as an independent evaluator for a protein design campaign using its Claude Opus 4.8 and Mythos Preview artificial intelligence models, further validating Twist's capabilities in AI-driven applications1

1

. Watch for increased adoption of predictive modeling tools across biotech companies seeking to compress drug candidate selection timelines and reduce development costs.